Acurx Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

6 Months Ended

Jun. 30, 2024

NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of June 30, 2024 and December 31, 2023 were as follows:


	June 30, 2024		December 31, 2023
Accrued research and development	$	2,976,379	$	2,263,934
Accrued professional fees		124,096		58,388
Accrued compensation expenses		42,308		716,307
Other accounts payable and accrued expenses		10,134		3,809
Total	$	3,152,917	$	3,042,438